142 related articles for article (PubMed ID: 20950371)
1. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Vizio B; Novarino A; Giacobino A; Cristiano C; Prati A; Brondino G; Ciuffreda L; Bellone G
Cancer Sci; 2010 Nov; 101(11):2448-54. PubMed ID: 20950371
[TBL] [Abstract][Full Text] [Related]
2. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.
Bellone G; Novarino A; Chiappino I; Gramigni C; Carbone A; Addeo A; Tonel E; Bertetto O; Emanuelli G
Anticancer Res; 2005; 25(5):3287-91. PubMed ID: 16101140
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
4. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.
Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F
Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
6. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus.
Robak E; Kierstan M; Cebula B; Krawczynska A; Sysa-Jedrzejowska A; Wierzbowska A; Smolewski P; Robak T
Lupus; 2009 Apr; 18(4):332-41. PubMed ID: 19276301
[TBL] [Abstract][Full Text] [Related]
7. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.
Starlinger P; Brugger P; Schauer D; Sommerfeldt S; Tamandl D; Kuehrer I; Schoppmann SF; Gnant M; Brostjan C
Neoplasia; 2011 May; 13(5):419-27. PubMed ID: 21532882
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Nixon AB; Pang H; Starr MD; Friedman PN; Bertagnolli MM; Kindler HL; Goldberg RM; Venook AP; Hurwitz HI;
Clin Cancer Res; 2013 Dec; 19(24):6957-66. PubMed ID: 24097873
[TBL] [Abstract][Full Text] [Related]
9. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
[TBL] [Abstract][Full Text] [Related]
10. [Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas].
Poreba M; Jaźwiec B; Kuliczkowski K; Poreba R
Pol Arch Med Wewn; 2005 Jan; 113(1):27-34. PubMed ID: 16130598
[TBL] [Abstract][Full Text] [Related]
11. Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
Ramcharan KS; Lip GY; Stonelake PS; Blann AD
Br J Cancer; 2014 Oct; 111(9):1742-9. PubMed ID: 25211664
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Najjar F; Al-Massarani G; Banat I; Alammar M
Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
[TBL] [Abstract][Full Text] [Related]
16. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
